IXICO plc Notice of results (1224Y)
May 11 2021 - 2:00AM
UK Regulatory
TIDMIXI
RNS Number : 1224Y
IXICO plc
11 May 2021
IXICO plc
("IXICO" or the "Company")
Notice of results
Investor presentation
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , confirms it will announce its half-year
results for the six months ended 31 March 2021 on Tuesday 25 May
2021.
Investor briefing
IXICO will be hosting a live online presentation open to all
investors on Tuesday 25 May at 3.30pm (BST). The presentation will
be delivered by Giulio Cerroni, Chief Executive Officer, Grant
Nash, Chief Financial Officer and Robin Wolz, Chief Scientific
Officer.
The Company is committed to providing an opportunity for all
existing and potential investors to hear directly from management
on the recent developments and additionally providing an update on
the business. The presentation will be hosted through the digital
platform Investor Meet Company.
Investors can sign up to Investor Meet Company for free and add
to meet IXICO plc via the following link:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO plc on the Investor Meet
Company platform will automatically be invited.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicoNews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGPURGAUPGGWU
(END) Dow Jones Newswires
May 11, 2021 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024